10 results about "Intra peritoneal" patented technology

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.

A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing, a first polymer that includes analyte indicator molecules and covers at least a portion of the housing, and a second polymer that forms an interpenetrating network with the first polymer. The second polymer may prevent biological or protein interference of the sensor.

This invention relates to pharmaceutical compositions and methods for treating or preventing autoimmune diseases in patients or subjects in need, said pharmaceutical compositions comprising: a 5-benzylaminosalicylic acid compound represented by chemical formula (I) or a pharmaceutically acceptable salt thereof; and, for example, a pharmaceutically acceptable carrier suitable for oral, intraperitoneal, or intravenous administration. Compositions comprising a 5-benzylaminosalicylic acid compound of chemical formula (I) or a pharmaceutically acceptable salt thereof can be used to treat autoimmune diseases.

The application provides a new crown vaccine carrier and application thereof. Composed of SARS-CoV-2 RBD as an antigen and STING agonist diABZI coupled with yeast beta-glucan particles. Compared with the diABZI-RBD vaccine alone, the GP-diABZI-RBD vaccine shows sustained vaccine release and elicits a more persistent immune response in mice. Intraperitoneal injection of GP-diABZI-RBD in mice can cause significant cellular and humoral immune responses. Using a replicable virus-like particle system based on pseudovirus particles, we determined that this vaccine can effectively induce effective and persistent neutralizing antibodies against the prototype and VOC, respectively. In particular, the prototype RBD antigen provided by the GP-diABZI-RBD vaccine shows a stronger and longer humoral immune response and antiviral protection.

A method of treating metabolic dysfunction-associated steatotic liver disease in a patient, reducing hepatic fat accumulation in a patient, and / or eliminating hepatic fat in a patient can include administering a therapeutically effective amount of Pam3CysSerLys4 (Pam3CSK4) to the patient in need thereof. The therapeutically effective amount of Pam3CysSerLys4 may be administered via an Intraperitoneal (IP) injection.

A surgical device or a portion of a surgical device places a purse string suture in tissue within a body (e.g., an intraperitoneal space). The surgical device includes or a distal end effector for a surgical device includes a jaw assembly, a staple cartridge, and a suture.

An Umbilical cord derived mesenchymal stem cell (UC-MSC) conditioned media (UC- MSC-CM) composition of the range from 5%-100% possessing immunomodulatory effect inhibiting tumour growth when administered intraperitoneally and intravenously. MSC- CM arrests cell cycle in leukaemia cells (K-562 and HL-60), lung cancer cells (A549 and HOP-62), breast cancer cells (MDA-MB-231 and MCF-7) and cervical cancer cells (HeLa). Elevated levels of IL-6, TIM3 and TIMP2 in MSC-CM confer to its immunomodulatory function by leading to an increase in expression of activation markers, cytotoxic granules, mucosal associated invariant T cells and decreasing the inflammasome pathway activation, consequently decreasing the levels of innate immune inflammasome pathway molecules in treated xenograft tumor tissues. MSC-CM as an adjunct with IL-12 augments cytotoxic potential against cancer cell lines. Tumor inhibition effect of MSC-CM is shown by significant reduction of relative tumor volume which is expressed by fold change of genes involved in various pathways affecting xenograft tumor growth.

The invention discloses an auxiliary purse-string suturing device for peritoneal dialysis catheterization, and relates to the field of peritoneal dialysis catheterization, the auxiliary purse-string suturing device comprises a mounting mechanism, the mounting mechanism comprises a mounting main rod, the surface of the mounting main rod is provided with an adjusting groove, the surface of the adjusting groove is provided with an adjusting mechanism, the adjusting mechanism comprises an adjusting ring and a fixing ring, and the fixing ring is provided with a fixing groove. The adjusting ring and the fixing ring are both sleeved with an adjusting groove in the surface of the mounting main rod, the fixing ring is fixedly connected with the adjusting groove, and the adjusting ring is slidably connected with the adjusting groove. According to the auxiliary purse-string suturing device for the peritoneal dialysis catheterization, the edge of the flexible protective skin is tightly buckled on the inner surface of the peritoneum, so that an intestinal canal and the omentum majus are isolated outside a suturing area, a closed compartment is established, medical staff can conveniently conduct peritoneal purse-string suturing in the protection area of the flexible protective skin, the risk of secondary injury is reduced, and the operation is convenient. And the opening size of the flexible protective leather can be flexibly adjusted, so that the device is suitable for auxiliary work of purse-string suture with different opening sizes.

The present disclosure provides a combination of a liposomal suspension, and of albumin, for use as bile acid sequestrants, wherein the use comprises (a) intraperitoneally administering the liposomal suspension to a subject in need thereof; and (b) intravenously or intraperitoneally administering the albumin to the subject; and (c) removing a dialysate containing liposomes and at least one bile acid from the subject, wherein the at least one bile acid comprises cholic acid, glycocholic acid, glycochenodeoxycholic acid or a combination of at least two thereof.